Chimeric antigen receptor T-cell therapy has been really instrumental in how we treat patients with myeloma. It has really changed the face of how we treat this disease, so since 2021, we've had two ...
A monoclonal T-cell receptor (TCR ... given the frequency of viral infections in patients with multiple myeloma after CAR T-cell therapy. The clonal TCRβ CDR3 sequence from both patients did ...
News Medical on MSN2d
Cancer-free for 18 years: CAR-T therapy sets new milestone in neuroblastoma treatmentA groundbreaking study in Nature Medicine reveals that GD2 CAR-T cell therapy can lead to long-term remission in children ...
The off-the-shelf chimeric antigen receptor T-cell therapy P-BCMA-ALLO1 was shown to be safe and elicited strong anti-tumor ...
During a Case-Based Roundtable® event, Muhammad Umair Mushtaq, MD, discussed managing long-term toxicity concerns related to ...
CAR T-cell therapy for cancer leads to similar safety and cancer outcomes in patients with and without preexisting autoimmune ...
An 18-year survivor of neuroblastoma, a solid childhood tumor that develops in immature nerve cells, is believed to represent ...
TG Therapeutics will use MaxCyte’s technology to advance toward a clinical trial its azer-cel CAR T-cell therapy for ...
T-cell therapy for eligible myeloma patients. The immunotherapy, which harnesses the body’s own immune system to fight blood cancer, will initially be available at HCA at University College Hospital ...
Researchers have identified a method to enhance the effectiveness of a promising cancer treatment. They found that modifying a specific gene improves the ability of immune cells to combat cancer for ...
The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...
T-cell therapy represents a groundbreaking advancement in the field of immuno-oncology. This innovative treatment involves ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback